Health Care Weekly: FDA, Lilly Debate Jurisdiction in Retatrutide Case; Interim Pathway for Wellness Peptide Compounding Mulled; CMS Gains Power to Ban Companies from Government Health Care Programs; Rule Proposed to Implement PBM Reimburse
The Health Care Weekly is a timely analysis of competition developments, policy changes and other updates that may affect medical and pharmaceutical markets. Key stories we’re…
DO
By Daniel Okafor · Regulatory Correspondent
Oct 21 03:00 ETSource: The Capitol Forum
From the source
Read at thecapitolforum.comHealth Care Weekly: FDA, Lilly Debate Jurisdiction in Retatrutide Case; Interim Pathway for Wellness Peptide Compounding Mulled; CMS Gains Power to Ban Companies from Government Health Care Programs; Rule Proposed to Implement PBM Reimburse
The Health Care Weekly is a timely analysis of competition developments, policy changes and other updates that may affect medical and pharmaceutical markets. Key stories we’re following this week include
